evidence table
Cocoa Flavanol Blood Pressure Meta-Analysis Evidence Table
Structured evidence table for Cocoa Flavanol Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Cocoa Flavanol Blood Pressure Meta-Analysis | 1 2 3 4 5 Metabolic syndrome (MetS) is characterized by the coexistence of cardiovascular risk factors and metabolic disorders, such as hypertension, insulin resistance, dyslipidemias – elevated triglyceride levels and reduced HDL levels – and increased waist circumference [,]. | 1 | Gomes Chagas Amanda (2026) | The effects of cocoa products in individuals with metabolic syndrome and related diseases: a systematic review and meta-analysis |
| Cocoa Flavanol Blood Pressure Meta-Analysis | The presence of MetS is a risk factor for other conditions, particularly increasing the risk of developing type 2 diabetes (DM2) by five times and the risk of cardiovascular diseases by three times []. | 1 | Gomes Chagas Amanda (2026) | The effects of cocoa products in individuals with metabolic syndrome and related diseases: a systematic review and meta-analysis |
| Cocoa Flavanol Blood Pressure Meta-Analysis | It may be the result from a combination of genetic factors, dietary profile, and physical inactivity []. | 1 | Gomes Chagas Amanda (2026) | The effects of cocoa products in individuals with metabolic syndrome and related diseases: a systematic review and meta-analysis |
| Cocoa Flavanol Blood Pressure Meta-Analysis | Cardiovascular diseases and metabolic dysfunction-associated steatotic liver disease (MASLD) are increasing sharply worldwide and share overlapping pathophysiological pathways, including oxidative stress, inflammation, hyperglycemia, obesity, dyslipidemia, and hypertension. | 4 | Tomaru JM (2026) | Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. |
| Cocoa Flavanol Blood Pressure Meta-Analysis | Based on these properties, this narrative review uniquely integrates evidence on chocolate's effects on both cardiovascular and hepatic health, exploring shared mechanisms and clinical implications. | 4 | Tomaru JM (2026) | Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. |
| Cocoa Flavanol Blood Pressure Meta-Analysis | Evidence from clinical studies suggests that chocolate modulates nitric oxide bioavailability and NADPH oxidase activity. | 4 | Tomaru JM (2026) | Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. |
| Cocoa Flavanol Blood Pressure Meta-Analysis | Dark chocolate, rich in cocoa flavanols such as epicatechin and catechin, exhibits antioxidant and anti-inflammatory effects. | 4 | Tomaru JM (2026) | Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. |
Source documents